Expression Of Aromatic L-amino Acid Decarboxylase Research Articles

Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules

As a widely used anticancer drug in the clinic, cisplatin has obvious side effects, especially nephrotoxicity. Previous studies have suggested that the accumulation of intracellular reactive oxygen species (ROS) is a hallmark of cisplatin-induced acute kidney injury. This study aimed to investigate the relationship between ROS accumulation induced by cisplatin and 5-HT degradation. In vivo, by HE and TUNEL staining, we found that cisplatin-induced renal lesions and apoptotic regions, which were located in proximal tubular epithelial cells, were also the regions in which tryptophan hydroxylase 1 (Tph1), aromatic l-amino acid decarboxylase (AADC), 5-HT2A receptor (5-HT2AR) and monoamine oxidase A (MAO-A) were overexpressed, as determined by immunohistochemistry. Notably, the 5-HT2AR antagonist sarpogrelate hydrochloride (SH) and the AADC inhibitor carbidopa (CDP) significantly attenuated cisplatin-induced increases in serum creatinine and blood urea nitrogen levels, renal ROS levels, oxidative stress (SOD activity and MDA), proinflammatory cytokine levels (NF-κB, TNF-α and IL-1β), proapoptotic factor levels (Bax, Bcl-2, C-caspase 3 and C-caspase 9) and the phosphorylation of p38 and STAT3, as well as renal lesions and apoptosis. The combination of SH and CDP could almost abolish the effects of cisplatin challenge. In vitro, the effects of cisplatin challenge and the inhibitory effects of SH and CDP were also observed in HK-2 cells. Additionally, similar to the combination of SH and CDP, the MAO-A inhibitor clorgyline could also abolish the effects of cisplatin challenge. More importantly, by western blotting, we detected that the upregulation of Tph1, AADC and MAO-A expression induced by cisplatin both in vivo and in vitro could be obviously suppressed by SH to decrease 5-HT synthesis and mitochondrial 5-HT degradation. Altogether, these findings suggested that cisplatin-induced nephrotoxicity is due to the activation of the 5-HT degradation system in proximal tubular epithelial cells, including 5-HT2AR and 5-HT synthesis and degradation. 5-HT2AR plays a role by mediating the expression of MAO-A and the 5-HT synthases Tph1 and AADC.

Treatment of Congenital Neurotransmitter Deficiencies by Intracerebral Ventricular Injection of an Adeno-Associated Virus Serotype 9 Vector

Dopamine and serotonin are produced by distinct groups of neurons in the brain, and gene therapies other than direct injection have not been attempted to correct congenital deficiencies in such neurotransmitters. In this study, we performed gene therapy to treat knock-in mice with dopamine and serotonin deficiencies caused by a mutation in the aromatic L-amino acid decarboxylase (AADC) gene (Ddc(KI) mice). Intracerebral ventricular injection of neonatal mice with an adeno-associated virus (AAV) serotype 9 (AAV9) vector expressing the human AADC gene (AAV9-hAADC) resulted in widespread AADC expression in the brain. Without treatment, 4-week-old Ddc(KI) mice exhibited whole-brain homogenate dopamine and serotonin levels of 25% and 15% of normal, respectively. After gene therapy, the levels rose to 100% and 40% of normal, respectively. The gene therapy improved the growth rate and survival of Ddc(KI) mice and normalized their hindlimb clasping and cardiovascular dysfunctions. The behavioral abnormalities of the Ddc(KI) mice were partially corrected, and the treated Ddc(KI) mice were slightly more active than normal mice. No immune reactions resulted from the treatment. Therefore, a congenital neurotransmitter deficiency can be treated safely through inducing widespread expression of the deficient gene in neonatal mice.

Safety and Tolerability of Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery of AAV2-hAADC with a Novel Delivery Platform in Nonhuman Primate Striatum

Degeneration of nigrostriatal neurons in Parkinson's disease (PD) causes progressive loss of aromatic l-amino acid decarboxylase (AADC), the enzyme that converts levodopa (l-DOPA) into dopamine in the striatum. Because loss of this enzyme appears to be a major driver of progressive impairment of response to the mainstay drug, l-DOPA, one promising approach has been to use gene therapy to restore AADC activity in the human putamen and thereby restore normal l-DOPA response in patients with PD. An open-label phase I clinical trial of this approach in patients with PD provided encouraging signs of improvement in Unified Parkinson's Disease Rating Scale scores and reductions in antiparkinsonian medications. However, such improvement was modest compared with the results previously reported in parkinsonian rhesus macaques. The reason for this discrepancy may have been that the relatively small volume of vector infused in the clinical study restricted the distribution of AADC expression, such that only about 20% of the postcommissural putamen was covered, as revealed by l-[3-(18)F]-α-methyltyrosine-positron emission tomography. To achieve more quantitative distribution of vector, we have developed a visual guidance system for parenchymal infusion of AAV2. The purpose of the present study was to evaluate the combined magnetic resonance imaging-guided delivery system with AAV2-hAADC under conditions that approximate the intended clinical protocol. Our data indicate that this approach directed accurate cannula placement and effective vector distribution without inducing any untoward effects in nonhuman primates infused with a high dose of AAV2-hAADC.

The role of TonEBP in regulation of AAD expression and dopamine production in renal proximal tubule cells upon hypertonic challenge

Renal proximal tubule cells overexpress aromatic l-amino acid decarboxylase (AAD) to produce dopamine, which inhibits salt absorption in the hypertonic environment. We examined the effect of TonEBP on AAD expression in human proximal tubule epithelial cells, HK-2 cell line. Confocal microscopy showed that after 2h of exposure to the hypertonic medium, TonEBP accumulation in nuclei increased as compared to the isotonic control. The activated TonEBP enhanced the mRNA expression of the representative downstream genes (i.e., SMIT and TauT). Meanwhile, AAD protein abundance also increased with TonEBP activation. EMSA and luciferase reporter assay showed that TonEBP was involved in transcriptional regulation of AAD upon hypertonic stress. Inactivation of TonEBP by the p38 inhibitor SB203580, or TonEBP shRNA significantly reduced AAD expression, which was rescued by re-expressing Myc-tagged TonEBP. Up-regulation of AAD increased dopamine synthesis, and dopamine inhibited NKA activity in hypertonic condition. These results suggested that TonEBP played an important role in the epithelial cells of renal proximal tubule upon hypertonic stress by enhancing AAD expression, which could promote dopamine secretion to negative regulate NKA activity. The elucidation of a new mechanism described in this study combined with previous findings provides more insights into this issue.

Mash1 is required for the differentiation of AADC-positive type III cells in mouse taste buds

Mash1 is expressed in subsets of neuronal precursors in both the central nervous system and the peripheral nervous system. However, involvement of Mash1 in taste cell differentiation has not previously been demonstrated. In this study, we investigated the role of Mash1 in regulating taste bud differentiation using Mash1 KO mice to begin to understand the mechanisms that regulate taste bud cell differentiation. We found that aromatic L-amino acid decarboxylase (AADC) cells were not evident in either the circumvallate papilla epithelia or in taste buds in the soft palates of Mash1 KO mice. However gustducin was expressed in taste buds in the soft palates of Mash1 KO mice. These results suggest that Mash1 plays an important role in regulating the expression of AADC in type III cells in taste buds, which supports the hypothesis that different taste bud cell types have progenitor cells that are specific to each cell type.

Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors

Gene therapies that utilize convention-enhanced delivery (CED) will require close monitoring of vector infusion in real time and accurate prediction of drug distribution. The magnetic resonance imaging (MRI) contrast agent, Gadoteridol (Gd), was used to monitor CED infusion and to predict the expression pattern of glial cell line-derived neurotrophic factor (GDNF) protein after administration of adeno-associated virus type 2 (AAV2) vector encoding human pre-pro-GDNF complementary DNA. The nonhuman primate (NHP) thalamus was utilized for modeling infusion to allow delivery of volumes more relevant to planned human studies. AAV2 encoding human aromatic L-amino acid decarboxylase (AADC) was coinfused with AAV2-GDNF/Gd to confirm regions of AAV2 transduction versus extracellular GDNF diffusion. There was a close correlation between Gd distribution and GDNF or AADC expression, and the ratios of expression areas of GDNF or AADC versus Gd were both close to 1. Our data support the use of Gd and MRI to monitor AAV2 infusion via CED and to predict the distribution of GDNF protein after AAV2-GDNF administration.

Aromatic l-amino acid decarboxylase expression profiling and isoform detection in the developing porcine brain

Aromatic l-amino acid decarboxylase (AADC) enzymatic activity is essential for the biosynthesis of the serotonin and dopamine neurotransmitters, and AADC activity is functionally associated with a number of human neuronal disorders. Here we describe the molecular characterization of AADC from the pig. Pig AADC shows a high degree of similarity to human and rodent AADC at the cDNA and protein level. Exon position shuffling has exchanged the location of the stop codon in pig AADC to the last exon 15 instead for the exon 14 position in the human, the rat, and the mouse AADC. Several pig AADC isoforms were identified, including the also in human described extraneuronal and neuronal isoforms generated by alternative splicing and alternative promoter usage. The AADC expression in the developing pig brain is highly expressed in the basal ganglia and the brain stem regions, and also significantly expressed in the cortex, the hippocampus and the cerebellum. Moreover, we observe that both the neuronal and the extraneuronal AADC mRNA isoforms were present at early brain developmental stages in the brain stem and the basal ganglia. This presents the first evidence that the non-neuronal AADC isoform also is expressed in the brain. Together our results propose that the porcine model is useful for future functional delineations of the AADC gene at the molecular level.

Co-Expression of Tyrosine Hydroxylase and GTP Cyclohydrolase I in Arginine Vasopressin-Synthesizing Neurons of the Human Supraoptic Nucleus Demonstrated by Laser Microdissection and Real-Time PCR

Tyrosine hydroxylase (TH), the first and limiting enzyme for catecholamine synthesis, has been identified immunohistochemically (IHC) in human neurosecretory neurons where it is found to colocalize with vasopressin (AVP) or oxytocin. TH expression shows striking interindividual variability and appears to depend on neuronal activation. Since GTP cyclohydrolase I (GCHI), the first enzyme for tetrahydrobiopterin synthesis, the essential cofactor of TH, and aromatic L-amino acid decarboxylase (AADC) have so far not been detected in neurosecretory neurons, the functional role of TH in catecholamine synthesis is still questionable. Our purpose was to investigate in postmortem hypothalamus whether GCHI and AADC mRNAs are co-expressed with TH in human AVP-synthesizing neurons. Total RNA was extracted from laser microdissected TH-IHC-identified neurons as well as from dissected parts of the dorsolateral supraoptic nucleus (dl-SON) of 12 control subjects, i.e. without known neurological, psychiatric or endocrinological illness. GCHI, AADC and TH mRNA expression was determined by real-time PCR. Our results showed that GCHI mRNA is co-expressed with TH in almost all cases that had a considerable number of TH-immunoreactive (TH-IR) neurosecretory neurons. A positive correlation was found between TH-immunohistochemical intensity and the presence of GCHI mRNA. AADC mRNA expression was detected only in microdissected areas of dl-SON in 2 cases that showed an increased number of TH-IR neurons. The co-expression of GCHI with TH indicates that TH is indeed active in human neurosecretory neurons. The apparent limited expression of AADC indicates that dopamine might be produced in human neurosecretory neurons under activation of the hypothalamoneurohypophyseal system, although the possibility that L-dopa is the final product cannot be excluded.

Immunohistochemical localization of aromatic l-amino acid decarboxylase in mouse taste buds and developing taste papillae

Aromatic L-amino acid decarboxylase (AADC) catalyses the decarboxylation of all aromatic L-amino acids. In mammals, AADC is expressed in many tissues besides the nervous system, and is associated with additional regulatory roles of dopamine and serotonin in a wide range of tissues. We examined the expression of AADC by using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. RT-PCR analysis showed that mRNA of AADC was detected in the taste bud-containing epithelium of the circumvallate papilla of mice. By immunohistochemical analyses, AADC was detected in a subset of taste bud cells of fungiform, foliate, and circumvallate papillae. Double-label studies showed that AADC colocalized with serotonin, NCAM, PLCbeta2, and PGP9.5. On the other hand, AADC never colocalized with alpha-gustducin. Our results of double staining with AADC and taste cell markers indicate that only the type III cells could convert 5-hydroxytryptophan (5-HTP) to serotonin within taste buds. Taken together with previous studies, the properties of the type III cell of taste buds exactly fit into the APUD (amine and amine precursor uptake and decarboxylation) cell scheme. Furthermore, in the developing circumvallate papilla, AADC are first detected in a small number of papillary epithelial cells at E14.5. By E18.5, AADC-positive epithelial cells also express PGP9.5, which is one of marker of taste cells, and these cells have been contacted by developing nerve fibers. These results suggest that AADC expression begins at early stages of taste bud cell differentiation, and biogenic amines may act on taste bud differentiation of tongue epithelial cells, and further may regulate innervation of taste bud progenitor cells.

215. Dimerizer-Regulated AADC Expression with Two AAV Vectors in 6-OHDA Lesioned Rats

Recombinant AAV vectors containing the dimerizer-inducible system of transcriptional activation provide a promising strategy for regulated control of therapeutic gene expression in the CNS. To test the feasibility of applying this approach to our current treatment for Parkinson's disease, we explored regulation of expression of the enzyme Aromatic L-Amino Acid Decarboxylase (AADC) in rat striatum by means of a regulated AAV vector system. Expression of the AADC transgene was made dependent on reconstitution of a functional transcription factor (TF) by the dimerizer rapamycin. Two vectors were constructed: 1) AAV-CMV-TF and 2) AAV-Z12-hAADC. We evaluated them in vivo in a rodent model of Parkinson's disease. A 1:1 combination (3 × 1010 vg of each vector) was infused ipsilaterally into unilaterally 6-OHDA-lesioned rats. Induction of transgene expression was achieved via intraperitoneal administration of rapamycin at designated time points. Since increased expression of AADC in the lesioned striatum correlates with increased conversion of L-dopa to dopamine, we would expect to see altered behavioral rotational response to 5mg/kg L-dopa. This parameter was evaluated six times during the course of the experiment. The rotational response to L-dopa in the vector-infused (+) rapamycin group was significantly increased (P<0.003, one-way ANOVA) above both control groups (vector-infused (–) rapamycin and excipient-infused animals). There was no significant difference between the two control groups, suggesting that expression of AADC in the absence of induction was not high enough to elicit behavioral response. Seven weeks following intrastriatal infusion rats were sacrificed and tissue was processed for immunostaining. Serial sections of fixed brain tissue were stained for AADC. We quantitated the spread volume and positive cell number for AADC transgene-derived immunostaining by stereology for each animal. The vector-infused (+) rapamycin group had the greatest number of AADC positive cells (75,825+/−30,506 cells), followed by a lower number of positive cells (31,000+/−25,812 cells) in the vector-infused (–) rapamycin group (P<0.01, one-way ANOVA), and no detectable expression in the excipient-infused control group. Intensity of staining appeared much lower in the non-induced vector-treated rats compared to those that received rapamycin. In summary, this study demonstrated robust behavioral response of parkinsonian rats to AAV-mediated AADC treatment that could be regulated using the rapamycin system. A low level of AADC transgene expression was observed in the absence of rapamycin, however, it was not significant enough to elicit behavioral response. Recombinant AAV vectors controlled by rapamycin or rapamycin analogs show promise as candidates for CNS therapies in which regulation of the transgene may be important.

50. AAV-Mediated Expression and Secretion of ADNF-9 Protects Substantia Nigra Neurons from 6-OHDA Damage

Parkinson's disease (PD) is a progressive movement disorder marked by selective degeneration of dopaminergic neurons of the substantia nigra and severe decrease in the dopamine (DA) content of the striatum. Replacement of DA is important to alleviate the motor symptoms of the disease. The DA precursor, L-3,4-dihydroxyphenylalanine (L-dopa), which is converted to DA by aromatic L-amino acid decarboxylase (AADC), provides clinical benefit to virtually all patients and has been mainstay in pharmacotherapy for PD. However, as the disease progresses, severe loss of dopaminergic nerve terminals is associated with an 80–95% depletion of striatal AADC activity resulting in loss of L-dopa efficacy. We demonstrated previously that AAV vector-mediated gene transfer of three DA-synthesizing enzymes, namely tyrosine hydroxylase, AADC, and GTP cyclohydrolase I, resulted in behavioral recovery in animal models of PD with efficient and long-term transduction of striatal neurons. In the present experiments, we investigated the therapeutic potential of the combination therapy, gene transfer of AADC with oral administration of L-dopa, in a primate bilateral model of PD. Cynomolgus macaques (Macaca fascicularis) were chronically treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) to make bilateral striatal lesions. Animals became behaviorally stable and motor symptoms did not ameliorate by the administration of L-dopa with peripheral AADC inhibitor. Then, adeno-associated virus (AAV) vector expressing AADC was injected into the unilateral putamen stereotaxically. Expression of AADC in the unilateral putamen resulted in remarkable improvement in manual dexterity on the contralateral to the AAV-AADC-injected side after the oral administration of L-dopa with peripheral AADC inhibitor. Fine motor task consists of capturing a piece of an apple improved on the contralateral hand with L-dopa. Amelioration of motor symptoms persisted about four hours each time after the oral intake of L-dopa. This duration of efficacy corresponds to the effective blood concentrations of the drug. Positron emission tomography showed remarkable and persistent increase of [11C]-L-dopa uptake in the AAV-AADC injected putamen. Gene transfer of AADC alone in combination with oral administration of L-dopa could be a shortcut to starting clinical trials of gene therapy for PD. With this method, patients still need to take L-dopa for the control of PD symptoms, but DA production can be regulated by the dose of L-dopa.

Circadian rhythm of aromatic L-amino acid decarboxylase in the rat suprachiasmatic nucleus: gene expression and decarboxylating activity in clock oscillating cells.

Aromatic L-amino acid decarboxylase (AADC) is the enzyme responsible for the decarboxylation step in both the catecholamine and indoleamine synthetic pathways. In the brain, however, a group of AADC containing neurones is found outside the classical monoaminergic cell groups. Since such non-monoaminergic AADC is expressed abundantly in the suprachiasmatic nucleus (SCN), the mammalian circadian centre, we characterized the role of AADC in circadian oscillation. AADC gene expression was observed in neurones of the dorsomedial subdivision of the SCN and its dorsal continuant in the anterior hypothalamic area. These AADC neurones could uptake exogenously applied L-DOPA and formed dopamine. AADC was co-expressed with vasopressin and the clock gene Per1 in the neurones of the SCN. Circadian gene expression of AADC was observed with a peak at subjective day and a trough at subjective night. The circadian rhythm of AADC enzyme activity in the SCN reflects the expression of the gene. Non-monoaminergic AADC in the SCN is expressed in clock oscillating cells, and the decarboxylating activity of master clock cells are under the control of the circadian rhythm.

Differential expression of the noradrenaline transporter in adrenergic chromaffin cells, ganglion cells and nerve fibres of the rat adrenal medulla

Expression of the noradrenaline transporter (NAT) was identified in various cell and fibre populations of the rat adrenal medulla, examined with immunohistochemistry and confocal microscopy. Immunoreactivity for the catecholamine biosynthetic enzymes tyrosine hydroxylase (TH), aromatic- l-amino-acid decarboxylase (AADC) and dopamine β-hydroxylase (DBH) was present in all chromaffin cells, while phenylethanolamine N-methyltransferase (PNMT) was used to determine adrenergic chromaffin cell groups. Labelling with NAT antibody was predominantly cytoplasmic and colocalised with PNMT immunoreactivity. Noradrenergic chromaffin cells were not NAT immunoreactive. Additionally, NAT antibody labelling demonstrated clusters of ganglion cells (presumably Type I) and nerve fibres. Expression of TH, AADC, DBH, PNMT and NAT mRNA was examined using reverse transcription-polymerase chain reaction (RT-PCR) from adrenal medulla punches and single chromaffin cells, and results were consistent with those obtained with immunocytochemistry. Chromaffin cells and fibres labelled with antibodies against growth associated protein-43 (GAP-43) were not NAT immunoreactive, while ganglion cells were doubled labelled with the two antibodies. The presence of NAT in adrenergic chromaffin cells, and its absence from noradrenergic cells, suggests that the adrenergic cell type is primarily responsible for uptake of catecholamines in the adrenal medulla.

The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models.

L-3,4-Dihydroxyphenylalanine (L-dopa) is the mainstay of therapy for patients with Parkinson's disease (PD), and mediates its primary effects through conversion into dopamine by aromatic L-amino acid decarboxylase (AADC). Given the loss of AADC-containing nigrostriatal dopaminergic neurons in PD, however, the location of residual AADC that converts L-dopa into dopamine remains controversial. The first objective of this study was to establish the presence of AADC expression in striatal neurons and glia using reverse transcriptase and PCR. Transcripts for the neuronal but not nonneuronal forms of AADC were detected in striatal tissue, cultured striatal neurons, and glia. We then examined whether this striatal AADC expression represents a physiologically significant source of dopaine production. No dopamine release was detected following incubation of striatal cultures with L-dopa or transduction with adenovirus expressing tyrosine hydoxylase. Our data establish the presence of AADC expression in the striatum both in vivo and in vitro, but suggest that striatal components do not represent a primary source of L-dopa decarboxylation following nigrostriatal denervation in rats. Understanding the source and localization of AADC is important in understanding the complications of L-dopa therapy and in designing rational therapeutic strategies for PD, including cellular transplantation and gene therapy.

Cyclooxygenase-2 Expression Inhibits Trophic Withdrawal Apoptosis in Nerve Growth Factor-differentiated PC12 Cells

Cyclooxygenase-2 (Cox-2), an enzyme responsible for catalyzing the committed step in prostanoid biosynthesis, is the product of an immediate early gene capable of being up-regulated by diverse stimuli. Significantly Cox-2 mRNA is absent from rat pheochromocytoma (PC12) cells, both basally and following stimulation with a range of agonists. Using PC12 cells engineered to stably express isopropyl-1-thio-beta-D-galactopyranoside-inducible Cox-2 (PCXII-4), we have investigated the putative effects of Cox-2 expression on differentiation, proliferation, and trophic withdrawal apoptosis. Cox-2 bioactivity had no effect on nerve growth factor-induced differentiation, epidermal growth factor-induced proliferation, or aromatic L-amino acid decarboxylase expression. However, trophic withdrawal apoptosis, induced by the removal of nerve growth factor following differentiation, was markedly reduced in the PCXII-4 when compared with control cells, as assessed by annexin V staining, DNA laddering, and Hoechst 33258 staining. The specificity of this effect was confirmed using two pharmacologically distinct nonsteroidal anti-inflammatory drugs, indomethacin and NS398. Investigations showed that the activity of the pro-apoptotic protease caspase-3 was reduced in PCXII cells. This study demonstrates that Cox-2-derived prostaglandins exert cytoprotective effects in trophic factor withdrawal apoptosis and provides evidence that this is, at least in part, due to suppression of caspase-3 activity.

Amantadine increases aromatic L-amino acid decarboxylase mRNA in PC12 cells.

Amantadine is an antiviral agent that was unexpectedly found to cause symptomatic improvement in patients with Parkinsonism, although its mechanism of action remains to be elucidated. Aromatic L-amino acid decarboxylase (AADC) is a regulated enzyme that catalyzes the decarboxylation of 3,4-dihydroxyphenylalanine (L-Dopa). It may be especially important during L-Dopa therapy in Parkinsonism, during which it may be rate-limiting for the production of dopamine. This study reports the effects of amantadine on the gene expression of AADC in PC12 cells. It shows that amantadine induces AADC gene expression at concentrations of 10 and 100 microM after 24 hr of incubation. The results suggest that the stimulation of AADC mRNA by amantadine may be one of its effects on dopamine metabolism that may have relevance for potentiation of L-Dopa therapy in Parkinsonism.

Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin.

Neuroendocrine differentiation of lung tumours is characterised by the expression of several neuroendocrine markers and is confined mostly to specific histological subtypes, i.e. small cell carcinomas and carcinoids. One of the markers seen in neuroendocrine tumours, high activity of the aromatic L-amino acid decarboxylase (AADC), is helpful in distinguishing the classic and variant small cell lung tumour subtypes. Here, we have analysed the expression and quantified the level of mRNA coding for AADC in human tumour cell lines by use of the reverse transcription and polymerase chain reaction (RT-PCR). High amounts of mRNA were detected in classic small cell lung carcinomas and a neuroblastoma cell line. Other cell lines (melanomas, non-small cell lung carcinomas and osteosarcoma) also showed AADC expression, but the levels were 2-3 orders lower. Also, the tissue-specific (neuronal versus liver-specific) mRNA type has been estimated. Small cell lung carcinomas, neuroblastoma and melanoma expressed messenger RNA specific for neuronal tissues. Importantly, the non-small cell lung carcinoma cell lines expressed either liver-specific (non-neuronal) mRNA (cell line A549) or predominantly the neuronal (cell line NCI-H520) AADC message. These data indicate that a range of tumour cell lines transcribe the AADC gene and that two distinct types of AADC mRNA which reflect the embryonal (neuronal or non-neuronal) origin of the tumour may be produced in non-small cell lung cancer cells.

Reciprocal regulation of the content of aromatic L-amino acid decarboxylase and tyrosine hydroxylase mRNA by NGF in PC12 cells

Aromatic L-amino acid decarboxylase (AADC) and tyrosine hydroxylase (TH) are involved in the synthesis of dopamine and other monoamine neurotransmitters, and their activities can be regulated by a number of physiological stimuli. An interesting finding has been that (-)-deprenyl and some other irreversible monoamine B oxidase inhibitors increase AADC gene expression and that these compounds can exert neuronal protection/rescue effects. In this study, we have investigated the effects of nerve growth factor (NGF), and of (-)-deprenyl on AADC and TH gene expression in PC12 cells. Cells were treated with different doses of NGF (0.2-50 ng/ml) for up to 3 days. Northern and blot hybridizations were performed to detect AADC and TH mRNA. The results show that NGF can down-regulate AADC gene expression while increasing TH gene expression in a time- and dose-dependent fashion. Treatment with (-)-deprenyl alone increases the gene expression of AADC, and (-)-deprenyl further counteracts the reductions induced by NGF. This study introduces novel results with regard to the regulation of the gene expression of AADC in PC12 cells, which is not paralleled by the other catecholamine biosynthetic enzymes. These findings support the existence of an interaction between NGF and AADC gene expression that may be associated with the process of neuronal degeneration or regeneration.

Analysis of an alternative promoter that regulates tissue-specific expression of the human aromatic L-amino acid decarboxylase gene in cultured cell lines.

The human aromatic L-amino acid decarboxylase (AADC) gene is transcribed in a tissue-specific manner by an alternative promoter. In this study using human cultured cell lines, we analyzed the alternative promoter that regulates tissue-specific expression of AADC. Neither neuronal nor nonneuronal-type mRNA of AADC was detected in HeLa cells, nonneuronal-type mRNA of AADC was expressed in HepG2 cells, and the neuronal-type was expressed in the SK-N-SH cell line. We examined the promoter activities located in 5'- and 3'-flanking regions of exon N1 and exon L1 by transfection experiments. Plasmids containing 5'-flanking regions of exon L1, the shortest of which was 0.3 kb, could promote specifically high expression of the reporter gene HepG2 cells. On the other hand, plasmids containing 5'-flanking regions of exon N1 (3.6 kb to 0.5 kb) could promote the reporter gene expression not only in SK-N-SH cells but also in HeLa and HepG2. More enhanced expression were observed by transfection of plasmids containing parts of the first intron in these cell lines. Thus, these results suggest that the basal liver-specific promoter activity is located in the 5'-flanking region of exon L1 and that the first intron may also be needed for enhanced expression rather than determination of cell-specificity.

Analysis of the Alternative Promoters that Regulate Tissue‐Specific Expression of Human Aromatic l‐Amino Acid Decarboxylase

Previously we identified two alternative first exons (exon N1 and exon L1) coding for 5' untranslated regions of human aromatic L-amino acid decarboxylase (AADC) and found that their alternative usage produced two types of mRNAs in a tissue-specific manner. To determine the cis-acting element regulating the tissue-specific expression of human AADC, we produced three kinds of transgenic mice harboring 5' flanking regions of the human AADC gene fused to the bacterial chloramphenicol acetyltransferase (CAT) gene. The transgene termed ACA contained -7.0 kb to -30 bp in exon N1, including the entire exon L1; ACN contained -3.6 kb to -30 bp in exon N1; and ACL contained -2.8 kb to -42 bp in exon L1. The ACA transgenic mice expressed CAT at extremely high levels in peripheral nonneuronal tissues, such as pancreas, liver, kidney, small intestine, and colon, that contained endogenous high AADC activity, whereas CAT immunoreactivity was not detected in either catecholaminergic or serotonergic neurons in the CNS. Thus, it was suggested that the ACA transgene contained the major part of cis-regulatory elements for the expression of AADC in peripheral nonneuronal tissues. On the other hand, the ACN transgenic mice moderately expressed CAT in various tissues except for the lung and liver, and the ACL transgenic mice showed moderate CAT expression only in the kidney.